Cargando…

Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration

C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Carr, Alice L.J., Inshaw, Jamie R.J., Flaxman, Christine S., Leete, Pia, Wyatt, Rebecca C., Russell, Lydia A., Palmer, Matthew, Prasolov, Dmytro, Worthington, Thomas, Hull, Bethany, Wicker, Linda S., Dunger, David B., Oram, Richard A., Morgan, Noel G., Todd, John A., Richardson, Sarah J., Besser, Rachel E.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233242/
https://www.ncbi.nlm.nih.gov/pubmed/35499624
http://dx.doi.org/10.2337/db22-0097
_version_ 1784735717937643520
author Carr, Alice L.J.
Inshaw, Jamie R.J.
Flaxman, Christine S.
Leete, Pia
Wyatt, Rebecca C.
Russell, Lydia A.
Palmer, Matthew
Prasolov, Dmytro
Worthington, Thomas
Hull, Bethany
Wicker, Linda S.
Dunger, David B.
Oram, Richard A.
Morgan, Noel G.
Todd, John A.
Richardson, Sarah J.
Besser, Rachel E.J.
author_facet Carr, Alice L.J.
Inshaw, Jamie R.J.
Flaxman, Christine S.
Leete, Pia
Wyatt, Rebecca C.
Russell, Lydia A.
Palmer, Matthew
Prasolov, Dmytro
Worthington, Thomas
Hull, Bethany
Wicker, Linda S.
Dunger, David B.
Oram, Richard A.
Morgan, Noel G.
Todd, John A.
Richardson, Sarah J.
Besser, Rachel E.J.
author_sort Carr, Alice L.J.
collection PubMed
description C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archival Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7–12, ≥13 years) across increasing diabetes durations. The proportion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age group (<1-year duration: age <7 years: 18 of 20 [90%], 7–12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1–5 years postdiagnosis: <7 years: 172 of 522 [33%], 7–12 years: 604 of 995 [61%], ≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those diagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells <1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7–12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1–5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7–12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β-cell retention and function.
format Online
Article
Text
id pubmed-9233242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-92332422022-07-08 Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration Carr, Alice L.J. Inshaw, Jamie R.J. Flaxman, Christine S. Leete, Pia Wyatt, Rebecca C. Russell, Lydia A. Palmer, Matthew Prasolov, Dmytro Worthington, Thomas Hull, Bethany Wicker, Linda S. Dunger, David B. Oram, Richard A. Morgan, Noel G. Todd, John A. Richardson, Sarah J. Besser, Rachel E.J. Diabetes Pathophysiology C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archival Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7–12, ≥13 years) across increasing diabetes durations. The proportion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age group (<1-year duration: age <7 years: 18 of 20 [90%], 7–12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1–5 years postdiagnosis: <7 years: 172 of 522 [33%], 7–12 years: 604 of 995 [61%], ≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those diagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells <1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7–12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1–5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7–12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β-cell retention and function. American Diabetes Association 2022-07 2022-05-02 /pmc/articles/PMC9233242/ /pubmed/35499624 http://dx.doi.org/10.2337/db22-0097 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://diabetesjournals.org/journals/pages/license.
spellingShingle Pathophysiology
Carr, Alice L.J.
Inshaw, Jamie R.J.
Flaxman, Christine S.
Leete, Pia
Wyatt, Rebecca C.
Russell, Lydia A.
Palmer, Matthew
Prasolov, Dmytro
Worthington, Thomas
Hull, Bethany
Wicker, Linda S.
Dunger, David B.
Oram, Richard A.
Morgan, Noel G.
Todd, John A.
Richardson, Sarah J.
Besser, Rachel E.J.
Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title_full Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title_fullStr Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title_full_unstemmed Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title_short Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration
title_sort circulating c-peptide levels in living children and young people and pancreatic β-cell loss in pancreas donors across type 1 diabetes disease duration
topic Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233242/
https://www.ncbi.nlm.nih.gov/pubmed/35499624
http://dx.doi.org/10.2337/db22-0097
work_keys_str_mv AT carralicelj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT inshawjamierj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT flaxmanchristines circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT leetepia circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT wyattrebeccac circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT russelllydiaa circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT palmermatthew circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT prasolovdmytro circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT worthingtonthomas circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT hullbethany circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT wickerlindas circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT dungerdavidb circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT oramricharda circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT morgannoelg circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT toddjohna circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT richardsonsarahj circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration
AT besserrachelej circulatingcpeptidelevelsinlivingchildrenandyoungpeopleandpancreaticbcelllossinpancreasdonorsacrosstype1diabetesdiseaseduration